← FDA DRUG APPROVALS

FDA NDA · NDA219500

ENBUMYST

bumetanide

Sponsor: CORSTASIS THERAP

APPLICATION
NDA219500
TYPE
NDA
ORIGINAL APPROVAL
2025-09-12
LATEST ACTION
2025-09-12
ROUTE
NASAL
DOSAGE FORM
SPRAY
MARKETING STATUS
Prescription

Products

ENBUMYST · ReferencePrescription
BUMETANIDE 0.5MG/SPRAY · SPRAY · NASAL

Approval history

2025-09-12Type 3 - New Dosage Form · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →